Estados Unidos · Plataformas y datos · MarketBeat
Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing

Resumen detallado
Solid Biosciences (NASDAQ:SLDB) plans to meet with the U.S. Food and Drug Administration before the end of 2026 to discuss a potential accelerated approval pathway for its Duchenne muscular dystrophy gene therapy, CEO Bo Cumbo said at a Jefferies fireside chat. The company has dosed 53 patients wit
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)




